332 related articles for article (PubMed ID: 22926712)
1. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Timmers HJ; Hindié E; Guillet BA; Neumann HP; Walz MK; Opocher G; de Herder WW; Boedeker CC; de Krijger RR; Chiti A; Al-Nahhas A; Pacak K; Rubello D;
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1977-95. PubMed ID: 22926712
[TBL] [Abstract][Full Text] [Related]
2. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Hicks RJ; Hindié E; Guillet BA; Avram A; Ghedini P; Timmers HJ; Scott AT; Elojeimy S; Rubello D; Virgolini IJ; Fanti S; Balogova S; Pandit-Taskar N; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2112-2137. PubMed ID: 31254038
[TBL] [Abstract][Full Text] [Related]
3. Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2223-2224. PubMed ID: 31332495
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
[TBL] [Abstract][Full Text] [Related]
5. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
[TBL] [Abstract][Full Text] [Related]
6. Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome.
Levine DS; Metzger DL; Nadel HR; Oviedo A; Adam MJ; Skarsgard E
Pediatr Radiol; 2011 Oct; 41(10):1321-5. PubMed ID: 21567141
[TBL] [Abstract][Full Text] [Related]
7. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.
Cuccurullo V; Mansi L
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1262-5. PubMed ID: 22644715
[No Abstract] [Full Text] [Related]
8. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C
Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
[TBL] [Abstract][Full Text] [Related]
9. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
Ryder SJ; Love AJ; Duncan EL; Pattison DA
Clin Endocrinol (Oxf); 2021 Jul; 95(1):13-28. PubMed ID: 33296100
[TBL] [Abstract][Full Text] [Related]
10. Multimodality Radionuclide Imaging in a Patient With Hereditary Paraganglioma-Pheochromocytoma Syndrome.
Yim SY; Moncayo VM; Pasquel FJ; Halkar RK
Clin Nucl Med; 2017 Dec; 42(12):964-965. PubMed ID: 28902732
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian look at the new 2019 guidelines for imaging of pheochromocytoma/paraganglioma with emphasis on extra-adrenal disease.
Ilias I; Meristoudis G
Hell J Nucl Med; 2019; 22(2):142. PubMed ID: 31273358
[TBL] [Abstract][Full Text] [Related]
12. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
13. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT.
Fikri AS; Kroiss A; Ahmad AZ; Zanariah H; Lau WF; Uprimny C; Donnemiller E; Kendler D; Nordin AJ; Virgolini IJ
Acta Radiol; 2014 Jun; 55(5):631-40. PubMed ID: 24037430
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
15. Imaging of pheochromocytoma and paraganglioma.
Brink I; Hoegerle S; Klisch J; Bley TA
Fam Cancer; 2005; 4(1):61-8. PubMed ID: 15883712
[TBL] [Abstract][Full Text] [Related]
16. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.
Van Laere K; Varrone A; Booij J; Vander Borght T; Nobili F; Kapucu OL; Walker Z; Någren K; Tatsch K; Darcourt J
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):434-42. PubMed ID: 19838704
[TBL] [Abstract][Full Text] [Related]
17. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.
Timmers HJ; Taieb D; Pacak K
Horm Metab Res; 2012 May; 44(5):367-72. PubMed ID: 22399235
[TBL] [Abstract][Full Text] [Related]
18. Pheochromocytoma and paraganglioma: imaging characteristics.
Baez JC; Jagannathan JP; Krajewski K; O'Regan K; Zukotynski K; Kulke M; Ramaiya NH
Cancer Imaging; 2012 May; 12(1):153-62. PubMed ID: 22571874
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions.
Gabriel S; Blanchet EM; Sebag F; Chen CC; Fakhry N; Deveze A; Barlier A; Morange I; Pacak K; Taïeb D
Clin Endocrinol (Oxf); 2013 Aug; 79(2):170-7. PubMed ID: 23230826
[TBL] [Abstract][Full Text] [Related]
20. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.
Darcourt J; Booij J; Tatsch K; Varrone A; Vander Borght T; Kapucu OL; Någren K; Nobili F; Walker Z; Van Laere K
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):443-50. PubMed ID: 19838702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
